Article 20 - CONTROLLED SUBSTANCES
- Section 68-20-1 - Definitions
- Section 68-20-2 through 68-20-4 - Revoked
- Section 68-20-5 - Revoked
- Section 68-20-6 - Revoked
- Section 68-20-7 - Revoked
- Section 68-20-8 - Revoked
- Section 68-20-8a - Revoked
- Section 68-20-8b and 68-20-8c - Revoked
- Section 68-20-9 - Fees for registration and reregistration
- Section 68-20-10 - Requirements of registration
- Section 68-20-10a - Electronic transmission of a controlled substance prescription
- Section 68-20-11 - Applications for registration
- Section 68-20-12 - Revoked
- Section 68-20-13 - Hearings generally
- Section 68-20-14 - Modification, transfer and termination of registration
- Section 68-20-15 - Revoked
- Section 68-20-15a - Security requirements
- Section 68-20-15b - Notification to board; suspected diversion, theft, or loss of controlled substances
- Section 68-20-16 - Records and inventories of registrants
- Section 68-20-17 - Order forms
- Section 68-20-18 - Information concerning prescriptions
- Section 68-20-18a - Information concerning prescriptions; recordkeeping; pharmacy prescription application
- Section 68-20-19 - Controlled substances listed in schedule II
- Section 68-20-20 - Controlled substances listed in schedules III, IV, and V
- Section 68-20-21 - [Revoked]
- Section 68-20-22 - Selling without a prescription
- Section 68-20-23 - [Revoked]
- Section 68-20-31 - [Revoked]
- Section 68-20-32 - 8-bromo-6-(2-fuorophenyl)-1-methyl-4H-benzo[f] [1,2,4]triazolo[4,3-a][1,4]diazepine included in schedule I
- Section 68-20-33 - 6-(2-chlorophenyl)-1-methyl-8-nitro-4 H -benzo[ f] [1,2,4]triazolo[4,3- a ][1,4]diazepine included in schedule I